Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Seres Therapeutics, Inc.MCRB · Entity 7191 | Chief Technology Officer & EVP | January 29, 2020 | January 31, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Seres Therapeutics, Inc.
Report date January 29, 2020 · Filed January 31, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| STOCK OPTION (RIGHT TO BUY)SEC Table II · derivative / convertible security · Conversion / exercise price $3.30 · Expires 2030-01-28 | Direct | 300,000 |
Reported balance
After 2020-01-29 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-01-29 · Grant · Acquired 300,000 · Balance 300,000 F1: The option will vest as to 25% of the shares on January 29, 2021. The remainder of the shares will vest in 12 equal quarterly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: The option will vest as to 25% of the shares on January 29, 2021. The remainder of the shares will vest in 12 equal quarterly installments thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 29, 2020 Filed Jan 31, 2020 21:05 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | GrantSTOCK OPTION (RIGHT TO BUY) · Derivative | 300,000 | $0.00 Strike: $3.30 | $0.00 |
DisclosureSEC source: 0000899243-20-002418 · doc4.xml · derivative · entry 1 Aunins John G. · CIK 0001643756 · Chief Technology Officer & EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2030-01-28 F1 · derivative.exercise_date: The option will vest as to 25% of the shares on January 29, 2021. The remainder of the shares will vest in 12 equal quarterly installments thereafter. Read SEC document |
| January 26, 2020 Filed Jan 28, 2020 21:05 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionRESTRICTED STOCK UNITS · Derivative | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-002210 · doc4.xml · derivative · entry 2 Aunins John G. · CIK 0001643756 · Chief Technology Officer & EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F2 · derivative.exercise_date: The restricted stock units are fully vested and do not have an expiration date. F2 · derivative.expiration_date: The restricted stock units are fully vested and do not have an expiration date. Read SEC document |
| January 26, 2020 Filed Jan 28, 2020 21:05 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionCOMMON STOCK | 12,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-002210 · doc4.xml · nonDerivative · entry 1 Aunins John G. · CIK 0001643756 · Chief Technology Officer & EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| January 26, 2019 Filed Jan 29, 2019 23:51 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionRESTRICTED STOCK UNITS · Derivative | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-002137 · doc4.xml · derivative · entry 3 Aunins John G. · CIK 0001643756 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 7,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F3 · derivative.exercise_date: These restricted stock units have vested and settled or will vest and settle as to 20% of the restricted stock units on January 26, 2018, 30% on January 26, 2019, and 50% on January 26, 2020. F3 · derivative.expiration_date: These restricted stock units have vested and settled or will vest and settle as to 20% of the restricted stock units on January 26, 2018, 30% on January 26, 2019, and 50% on January 26, 2020. Read SEC document |
| January 26, 2019 Filed Jan 29, 2019 23:51 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionCOMMON STOCK | 7,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-002137 · doc4.xml · nonDerivative · entry 1 Aunins John G. · CIK 0001643756 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,750 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| January 25, 2019 Filed Jan 29, 2019 23:51 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | GrantSTOCK OPTION (RIGHT TO BUY) · Derivative | 60,000 | $0.00 Strike: $6.01 | $0.00 |
DisclosureSEC source: 0000899243-19-002137 · doc4.xml · derivative · entry 2 Aunins John G. · CIK 0001643756 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2029-01-24 F2 · derivative.exercise_date: The option will vest as to 25% of the shares on January 25, 2020. The remainder of the shares will vest in 12 equal quarterly installments thereafter. Read SEC document |
| December 19, 2018 Filed Dec 19, 2018 21:11 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionRESTRICTED STOCK UNITS · Derivative | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-031411 · doc4.xml · derivative · entry 3 Aunins John G. · CIK 0001643756 · Chief Technology Officer & EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: COMMON STOCK · 10,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents right to receive one share of Issuer common stock. F4 · derivative.exercise_date: These restricted stock units have vested and settled as to 25% of the restricted stock units on December 19, 2017, 25% on June 19, 2018; and 50% on December 19, 2018. F4 · derivative.expiration_date: These restricted stock units have vested and settled as to 25% of the restricted stock units on December 19, 2017, 25% on June 19, 2018; and 50% on December 19, 2018. Read SEC document |
| December 19, 2018 Filed Dec 19, 2018 21:11 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionCOMMON STOCK | 10,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-031411 · doc4.xml · nonDerivative · entry 2 Aunins John G. · CIK 0001643756 · Chief Technology Officer & EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Each restricted stock unit represents right to receive one share of Issuer common stock. Read SEC document |
| December 17, 2018 Filed Dec 19, 2018 21:11 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | SaleCOMMON STOCK | 14,282 | $6.39 | $91,313.40 |
DisclosureSEC source: 0000899243-18-031411 · doc4.xml · nonDerivative · entry 1 Aunins John G. · CIK 0001643756 · Chief Technology Officer & EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,250 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2018. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $6.2100 to $6.5900. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 15, 2018 Filed Nov 19, 2018 21:27 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | SaleCOMMON STOCK | 14,279 | $8.26 | $117,911.70 |
DisclosureSEC source: 0000899243-18-029310 · doc4.xml · nonDerivative · entry 1 Aunins John G. · CIK 0001643756 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,532 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2018. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $8.0600 to $8.4200. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 15, 2018 Filed Oct 16, 2018 20:16 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | SaleCOMMON STOCK | 14,279 | $5.94 | $84,800.13 |
DisclosureSEC source: 0000899243-18-026790 · doc4.xml · nonDerivative · entry 1 Aunins John G. · CIK 0001643756 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,811 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2018. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $5.6400 to $6.2912. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 17, 2018 Filed Sep 20, 2018 01:22 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | SaleCOMMON STOCK | 14,279 | $7.27 | $103,875.44 |
DisclosureSEC source: 0000899243-18-024819 · doc4.xml · nonDerivative · entry 3 Aunins John G. · CIK 0001643756 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,090 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2018. F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $7.0914 to $7.5600. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 15, 2018 Filed Sep 20, 2018 01:22 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | SaleCOMMON STOCK | 14,279 | $7.57 | $108,069.18 |
DisclosureSEC source: 0000899243-18-024819 · doc4.xml · nonDerivative · entry 2 Aunins John G. · CIK 0001643756 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,369 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2018. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $7.2500 to $7.7600. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. This filing is being reported late due to an inadvertent administrative error. Read SEC document |
| July 15, 2018 Filed Jul 18, 2018 20:58 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | SaleCOMMON STOCK | 14,279 | $8.10 | $115,725.58 |
DisclosureSEC source: 0000899243-18-020074 · doc4.xml · nonDerivative · entry 1 Aunins John G. · CIK 0001643756 · Chief Technology Officer & EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,927 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2018. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $7.82 to $8.60. The Reporting Persons undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 19, 2018 Filed Jun 19, 2018 21:03 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionRESTRICTED STOCK UNITS · Derivative | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-017198 · doc4.xml · derivative · entry 2 Aunins John G. · CIK 0001643756 · Chief Technology Officer & EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: COMMON STOCK · 5,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F2 · derivative.exercise_date: These restricted stock units have vested and settled or will vest and settle as to 25% of the restricted stock units on December 19, 2017, 25% on June 19, 2018; and 50% on December 19, 2018. F2 · derivative.expiration_date: These restricted stock units have vested and settled or will vest and settle as to 25% of the restricted stock units on December 19, 2017, 25% on June 19, 2018; and 50% on December 19, 2018. Read SEC document |
| June 19, 2018 Filed Jun 19, 2018 21:03 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionCOMMON STOCK | 5,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-017198 · doc4.xml · nonDerivative · entry 1 Aunins John G. · CIK 0001643756 · Chief Technology Officer & EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,206 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| June 15, 2018 Filed Jun 18, 2018 20:43 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | SaleCommon Stock | 14,279 | $8.57 | $122,325.34 |
DisclosureSEC source: 0000899243-18-017017 · doc4.xml · nonDerivative · entry 1 Aunins John G. · CIK 0001643756 · Chief Technology Officer & EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,206 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5 1 trading plan adopted by the Reporting Person on March 15, 2018. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $8.39 to $8.69. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 15, 2018 Filed Sep 20, 2018 01:22 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | SaleCOMMON STOCK | 14,279 | $8.08 | $115,400.02 |
DisclosureSEC source: 0000899243-18-024819 · doc4.xml · nonDerivative · entry 1 Aunins John G. · CIK 0001643756 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,648 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2018. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $7.8800 to $8.1400. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. This filing is being reported late due to an inadvertent administrative error. Read SEC document |
| April 25, 2018 Filed Apr 26, 2018 20:55 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | SaleCommon Stock | 14,279 | $7.58 | $108,266.23 |
DisclosureSEC source: 0000899243-18-010837 · doc4.xml · nonDerivative · entry 1 Aunins John G. · CIK 0001643756 · Chief Technology Officer & EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 184,485 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5 1 trading plan adopted by the Reporting Person on March 15, 2018. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $7.47 to $7.95. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 30, 2018 Filed Jan 31, 2018 02:01 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | GrantSTOCK OPTION (RIGHT TO BUY) · Derivative | 40,000 | $0.00 Strike: $10.42 | $0.00 |
DisclosureSEC source: 0000899243-18-002334 · doc4.xml · derivative · entry 4 Aunins John G. · CIK 0001643756 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: COMMON STOCK · 40,000 shares Expires 2028-01-29 F3 · derivative.exercise_date: The Option will vest as to 25% of the shares on January 30, 2019. The remainder of the shares will vest in 12 equal quarterly installments thereafter. Read SEC document |
| January 26, 2018 Filed Jan 31, 2018 02:01 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionRESTRICTED STOCK UNITS · Derivative | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-002334 · doc4.xml · derivative · entry 3 Aunins John G. · CIK 0001643756 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: COMMON STOCK · 5,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F2 · derivative.exercise_date: These restricted stock units have vested and settled or will vest and settle as to 20% of the restricted stock units on January 26, 2018, 30% on January 26, 2019; and 50% on January 26, 2020. F2 · derivative.expiration_date: These restricted stock units have vested and settled or will vest and settle as to 20% of the restricted stock units on January 26, 2018, 30% on January 26, 2019; and 50% on January 26, 2020. Read SEC document |
| January 26, 2018 Filed Jan 31, 2018 02:01 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | SaleCOMMON STOCK | 1,738 | $11.02 | $19,152.76 |
DisclosureSEC source: 0000899243-18-002334 · doc4.xml · nonDerivative · entry 2 Aunins John G. · CIK 0001643756 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 198,764 Read SEC document |
| January 26, 2018 Filed Jan 31, 2018 02:01 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionCOMMON STOCK | 5,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-002334 · doc4.xml · nonDerivative · entry 1 Aunins John G. · CIK 0001643756 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,502 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| December 19, 2017 Filed Dec 20, 2017 21:56 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionRestricted Stock Units · Derivative | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-029325 · doc4.xml · derivative · entry 3 Aunins John G. · CIK 0001643756 · Chief Technology Officer & EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 5,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F2 · derivative.exercise_date: These restricted stock units vest and settle as to 25% of the restricted stock units on December 19, 2017, 25% on June 19, 2018; and 50% on December 19, 2018. F2 · derivative.expiration_date: These restricted stock units vest and settle as to 25% of the restricted stock units on December 19, 2017, 25% on June 19, 2018; and 50% on December 19, 2018. Read SEC document |
| December 19, 2017 Filed Dec 20, 2017 21:56 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | SaleCommon Stock | 1,623 | $10.14 | $16,457.22 |
DisclosureSEC source: 0000899243-17-029325 · doc4.xml · nonDerivative · entry 2 Aunins John G. · CIK 0001643756 · Chief Technology Officer & EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,437 Read SEC document |
| December 19, 2017 Filed Dec 20, 2017 21:56 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionCommon Stock | 5,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-17-029325 · doc4.xml · nonDerivative · entry 1 Aunins John G. · CIK 0001643756 · Chief Technology Officer & EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,060 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| December 19, 2017 Filed Jan 31, 2018 01:54 UTC Amendment | Seres Therapeutics, Inc. MCRB · Entity 7191 | SaleCOMMON STOCK | 1,623 | $10.14 | $16,457.22 |
DisclosureSEC source: 0000899243-18-002323 · doc4a.xml · nonDerivative · entry 2 Aunins John G. · CIK 0001643756 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 195,502 F2 · balance_after: Due to a clerical error, the reporting person's original Form 4 filed on December 20, 2017 set forth an incorrect amount of common stock beneficially owned by the reporting person following the reported transaction. This Form 4/A corrects the error and presents the correct number of common stock beneficially owned by the reporting person following the reported transaction. Read SEC document |
| December 19, 2017 Filed Jan 31, 2018 01:54 UTC Amendment | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionCOMMON STOCK | 5,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-002323 · doc4a.xml · nonDerivative · entry 1 Aunins John G. · CIK 0001643756 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 197,125 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F2 · balance_after: Due to a clerical error, the reporting person's original Form 4 filed on December 20, 2017 set forth an incorrect amount of common stock beneficially owned by the reporting person following the reported transaction. This Form 4/A corrects the error and presents the correct number of common stock beneficially owned by the reporting person following the reported transaction. Read SEC document |
| June 19, 2017 Filed Jun 21, 2017 21:24 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | GrantRestricted Stock Units · Derivative | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-016868 · doc4.xml · derivative · entry 1 Aunins John G. · CIK 0001643756 · Chief Technology Officer & EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F2 · derivative.exercise_date: These restricted stock units vest and settle as to 25% of the restricted stock units on December 19, 2017; 25% on June 19, 2018; and 50% on December 19, 2018. F2 · derivative.expiration_date: These restricted stock units vest and settle as to 25% of the restricted stock units on December 19, 2017; 25% on June 19, 2018; and 50% on December 19, 2018. Read SEC document |
| January 26, 2017 Filed Jan 27, 2017 22:56 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | GrantRestricted Stock Units · Derivative | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-002128 · doc4.xml · derivative · entry 2 Aunins John G. · CIK 0001643756 · Chief Technology Officer & EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F3 · derivative.exercise_date: These restricted stock units vest as to 20% on January 26, 2018, 30% on January 26, 2019 and 50% on January 26, 2020. F3 · derivative.expiration_date: These restricted stock units vest as to 20% on January 26, 2018, 30% on January 26, 2019 and 50% on January 26, 2020. Read SEC document |
| January 26, 2017 Filed Jan 27, 2017 22:56 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $9.89 | $0.00 |
DisclosureSEC source: 0000899243-17-002128 · doc4.xml · derivative · entry 1 Aunins John G. · CIK 0001643756 · Chief Technology Officer & EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2027-01-25 F1 · derivative.exercise_date: The option will vest as to 25% of the shares on January 26, 2018. The remainder of the shares will vest in 12 equal quarterly installments thereafter. Read SEC document |
| September 19, 2016 Filed Sep 20, 2016 20:59 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $12.55 | $0.00 |
DisclosureSEC source: 0000899243-16-029446 · doc4.xml · derivative · entry 1 Aunins John G. · CIK 0001643756 · Chief Technology Officer & EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2026-09-18 F1 · derivative.exercise_date: The option will vest as to 25% of the shares on September 19, 2017. The remainder of the shares will vest in 12 equal quarterly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.